disease

AC Immune SA (NASDAQ:ACIU) on Thursday released interim safety and efficacy results from the Phase 2 VacSYn trial of its anti-alpha-synuclein (a-syn) active immunotherapy ACI-7104.056 in early Parkinson’s disease. • AC Immune stock is surging to new heights today. Why is ACIU stock up...

Pfizer Inc. (NYSE:PFE) on Wednesday shared detailed results from the Phase 3 HER2CLIMB-05 trial of Tukysa (tucatinib) as part of an investigational first-line maintenance treatment combination, following chemotherapy-based induction. • Pfizer shares are showing limited movement. Where is PFE...

Abivax SA’s (NASDAQ:ABVX) stock is trading higher on Wednesday. The stock reacted to market rumours that U.S. pharma giant Eli Lilly and Co (NYSE:LLY) could make an offer. • Abivax stock is charging ahead with explosive momentum. Check out ABVX shares here. The “share price...

Novartis AG (NYSE:NVS) on Tuesday shared results from the VAYHIT2 Phase 3 trial of ianalumab plus eltrombopag in patients with primary immune thrombocytopenia (ITP) previously treated with corticosteroids. In August, Novartis shared topline results from the VAYHIT2 trial. Ianalumab (9 mg/kg)...

Zenas BioPharma Inc. (NASDAQ:ZBIO) and InnoCare Pharma Ltd. on Wednesday announced a license agreement granting Zenas global development and commercialization rights to orelabrutinib for multiple sclerosis and across all therapeutic areas other than oncology. ZBIO is delivering impressive returns....

AstraZeneca Plc (NASDAQ:AZN) released on Wednesday topline data from RESOLUTE Phase 3 trial of Fasenra (benralizumab). AZN is showing upward bias. Get the complete picture here. Fasenra, despite showing numerical improvement, did not achieve statistical significance in the primary endpoint in...

Eli Lilly and Co. (NYSE:LLY) announced on Tuesday that it plans to build a $5 billion manufacturing facility just west of Richmond, Virginia, in Goochland County. The new facility will be Eli Lilly’s first fully integrated site dedicated to both active pharmaceutical...

Eli Lilly and Co (NYSE:LLY) on Monday shared topline results from the Phase 3 BRUIN CLL-313 clinical trial of Jaypirca (pirtobrutinib), a non-covalent (reversible) Bruton tyrosine kinase (BTK) inhibitor, versus chemoimmunotherapy (bendamustine plus rituximab), in treatment-naïve patients with...

The U.S. Food and Drug Administration (FDA) on Thursday granted Breakthrough Therapy designation to Eli Lilly and Co.’s (NYSE:LLY) olomorasib, in combination with Merck & Co. Inc.’s (NYSE:MRK) anti-PD-1 therapy Keytruda (pembrolizumab), for the first-line treatment of unresectable...

Gilead Sciences, Inc. (NASDAQ:GILD) on Wednesday announced a strategic partnership agreement with the Global Fund to Fight AIDS, Tuberculosis and Malaria to supply lenacapavir — Gilead’s twice-yearly injectable HIV-1 capsid inhibitor — for the prevention of HIV as pre-exposure prophylaxis (...

Capricor Therapeutics (NASDAQ:CAPR) on Friday released four-year safety and efficacy results from its ongoing HOPE-2 Open-Label Extension (OLE) study of Deramiocel, the company’s lead cell therapy candidate for Duchenne Muscular Dystrophy (DMD). After four years of continuous treatment,...

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted on Friday a positive opinion recommending approval for Madrigal Pharmaceuticals, Inc.’s (NASDAQ:MDGL) resmetirom (Rezdiffra) for adults with noncirrhotic MASH with moderate to advanced...

H.C. Wainwright analyst Brandon Folkes initiated coverage on Omeros Corporation (NASDAQ:OMER) with a Buy rating and a price forecast of $9. According to Brandon, Omeros holds significant long-term value potential due to its expansive rare disease pipeline. While the company has faced investor...

Arvinas, Inc. (NASDAQ:ARVN) on Friday announced in a press release the submission of a New Drug Application to the U.S. Food and Drug Administration (FDA) with its partner Pfizer Inc. (NYSE:PFE). The application covers vepdegestrant for patients with ER-positive (ER+)/human epidermal growth factor...

Valneva SE (NASDAQ:VALN) on Thursday announced six-month antibody persistence and safety data for its Phase 2 trial evaluating the safety and immunogenicity of two different dose levels of its single-shot chikungunya vaccine, Ixchiq, in 304 children, according to a press release. Partially funded...